GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Sale Of Business

GENinCode (LSE:GENI) Sale Of Business : £0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Sale Of Business?

GENinCode's sale of business for the six months ended in Jun. 2024 was £0.00 Mil. It means GENinCode gained £0.00 Mil from selling business. GENinCode's sale of business for the trailing twelve months (TTM) ended in Jun. 2024 was £0.00 Mil.

Compared with last quarter (£0.00 Mil in Dec. 2023 ), GENinCode gained the same money from selling business in Jun. 2024 (£0.00 Mil).


GENinCode Sale Of Business Historical Data

The historical data trend for GENinCode's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Sale Of Business Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
- - - - -

GENinCode Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Sale Of Business Get a 7-Day Free Trial Premium Member Only - - - - -

GENinCode Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GENinCode Sale Of Business Related Terms

Thank you for viewing the detailed overview of GENinCode's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


GENinCode Business Description

Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.